Compare JPMorgan Chase & Co (JPM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Vertex Pharmaceuticals Incorporated — how do they compare? JPMorgan Chase & Co trades at $361.85 (market cap $956.39B), while Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B). The key difference: JPMorgan Chase & Co is far larger — about 7.2× Vertex Pharmaceuticals Incorporated's market cap, and JPMorgan Chase & Co pays a 1.67% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| JPM | VRTX | |
|---|---|---|
Market Cap | $956.39B | $132.79B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $362.04 | $529.65 |
52-Week Low | $282.84 | $376.62 |
Dividend Yield | 1.67% | — |
Enterprise Value | — | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $359.79, up 0.63% today, with a bullish technical signal from moving averages and a consensus analyst price target of $374.18. Recent earnings show a Q2 2026 beat ($7.59 actual vs. $5.59 expected), though Q4 2025 missed estimates. Revenue grew to $181.85B in 2025, with a net income margin of 33.38% and ROE of 18.43%, but cash flow trends remain volatile with negative net cash flow in 2025.
The outlook is positive with strong profitability and analyst support, but risks include geopolitical tensions affecting oil markets and cybersecurity threats from AI advancements. The stock offers upside to the price target, yet investors should monitor cash flow stability and macroeconomic headwinds highlighted by CEO Jamie Dimon's recent warnings.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
